Pimavanserin — CAS 1231927-97-7

Pimavanserin is a selective serotonin 5-HT2A receptor inverse agonist/antagonist approved for treatment of Parkinson's disease psychosis (PDP). Manufactured by Mediocon Inc in Aurangabad, Maharashtra, India under GMP conditions, it is a novel antipsychotic without dopamine receptor activity. CAS No: 1231927-97-7.

• Treatment of hallucinations and delusions associated with Parkinson's disease psychosis
• Investigational use in Alzheimer's disease agitation and psychosis
• Research into serotonin receptor pharmacology and CNS disorders
• Potential use in major depressive disorder adjunctive therapy

• GMP Certified manufacturing facility in Aurangabad, Maharashtra, India
• Full pharmacopoeial compliance: IP / BP / USP standards
• Complete documentation: Certificate of Analysis (CoA), MSDS, Certificate of Origin
• Stringent in-process quality control at every manufacturing stage
• HPLC purity testing and spectroscopic identification (IR, NMR)
• Cold-chain and controlled-environment storage facilities available
• Exported to 40+ countries with full regulatory support